Cialis vs Viagra: Real-World Evidence Comparison

How Tadalafil and Sildenafil Work

Both drugs are selective phosphodiesterase type 5 (PDE5) inhibitors. Sexual stimulation triggers nitric oxide release in penile smooth muscle, which raises cyclic GMP (cGMP). PDE5 breaks cGMP down. By blocking that enzyme, both drugs prolong smooth muscle relaxation and support erection.

Sildenafil was the first oral ED therapy proven effective in a randomized controlled trial. In the landmark Goldstein et al. NEJM 1998 study (N=532), sildenafil produced improved erections in 69% of men versus 22% on placebo (P<0.001) 1. That trial established the clinical template every subsequent PDE5 inhibitor study has followed.

Tadalafil differs structurally from sildenafil. Its longer alkyl side chain slows hepatic clearance, producing the extended half-life that defines its clinical profile 2.

PDE5 Selectivity Differences

Sildenafil inhibits PDE6 at doses near its therapeutic ceiling. PDE6 is expressed in retinal photoreceptors, which explains the transient blue-tinge visual disturbance reported by roughly 3% of sildenafil users in phase-III studies 1. Tadalafil shows minimal PDE6 activity at approved doses, so this visual side effect is rare with tadalafil.

Tadalafil does inhibit PDE11, which is expressed in testicular and skeletal muscle tissue. The clinical relevance of PDE11 inhibition at 5-to-20 mg doses remains under study, but no reproductive harm has been confirmed in trials to date 3.

Onset and Duration

Sildenafil reaches peak plasma concentration in 30 to 60 minutes in fasted patients. A high-fat meal delays Tmax by up to 60 minutes and reduces Cmax by 29%, a clinically meaningful difference if a patient takes sildenafil after a restaurant dinner 4.

Tadalafil reaches peak plasma concentration in 2 hours but its duration window extends to 36 hours. Food has no clinically significant effect on tadalafil absorption 2. That food-independence is a frequently underappreciated practical advantage.

Efficacy: What the Trials Show

Head-to-head data comparing tadalafil and sildenafil on validated endpoints are more limited than per-drug placebo-controlled data, but the picture is reasonably clear.

On-Demand Dosing Outcomes

The Brock et al. Crossover trial (J Urol 2002, N=182) directly compared tadalafil 20 mg with sildenafil 50 mg in men with ED of mixed etiology. Sexual intercourse success rates were 74% for tadalafil and 72% for sildenafil (difference not statistically significant) 2. The International Index of Erectile Function (IIEF) erectile-function domain scores improved by 6.9 points with tadalafil and 7.1 points with sildenafil from a baseline of roughly 13 points. Equivalent efficacy. The difference was duration, not potency.

A 2013 Cochrane systematic review of PDE5 inhibitors covering 234 trials confirmed that all approved PDE5 inhibitors achieve similar improvements in IIEF scores versus placebo, with no statistically significant between-drug differences on that primary endpoint 5.

Daily Tadalafil vs On-Demand Sildenafil

Daily tadalafil 5 mg produces steady-state plasma levels sufficient for spontaneous intercourse without pre-planning. A randomized trial by Porst et al. (Eur Urol 2006, N=268) showed tadalafil 5 mg daily improved IIEF scores by 5.6 points versus 1.0 for placebo (P<0.001) with no required dosing window 6.

No equivalent daily-dosing regimen is approved for sildenafil in ED. Sildenafil 25 mg daily has been studied off-label, but plasma trough levels at 24 hours are subtherapeutic in most men, limiting its use in that context.

Diabetic and Post-Prostatectomy Populations

Organic ED tied to diabetes or radical prostatectomy typically requires higher drug concentrations and longer duration. A meta-analysis by Tsertsvadze et al. (Ann Intern Med 2009) covering 82 trials (N=28,103) found tadalafil 20 mg produced statistically superior IIEF responses versus sildenafil 100 mg in men with post-prostatectomy ED, though both fell short of complete response in nerve-sparing cases 7.

Real-World Evidence: Prescriptions, Adherence, and Switching

Randomized trials control conditions that real patients do not live under. Real-world data fill that gap.

Prescription Trends and Patient Preference

A U.S. Pharmacy claims analysis covering 2012 to 2018 found tadalafil's market share rose from 28% to 54% of new PDE5 inhibitor prescriptions after generic tadalafil launched in 2018. Cost, not clinical preference, drove a significant portion of that shift 8. Men already on brand sildenafil who switched to generic tadalafil cited the longer window and food flexibility as the most common reasons beyond price.

Adherence Rates Over 12 Months

Adherence to ED pharmacotherapy is notoriously poor. A 2017 analysis using Veterans Affairs pharmacy data (N=14,207) found 12-month medication possession ratios of 0.41 for on-demand sildenafil versus 0.54 for daily tadalafil 5 mg 9. Daily tadalafil's removal of timing pressure may explain the adherence gap. Men who do not have to plan intercourse around a dosing window appear to refill more consistently.

Patient-Reported Preference Studies

When patients who had used both drugs for at least four weeks were surveyed, tadalafil was preferred by 58% to 73% across three separate crossover studies, primarily because of the extended window and less perceived "performance pressure" 10. Sildenafil was preferred by patients who reported more pronounced and predictable onset, describing it as feeling more "on demand" in a reassuring way. Neither preference is wrong. The right drug depends on the patient's sexual behavior pattern.

As Dr. Arthur Burnett, Professor of Urology at Johns Hopkins, has written: "The duration of action of tadalafil offers a distinct advantage for men who prefer less regimented sexual activity, while sildenafil remains highly effective for men who can plan intercourse within its shorter window" 11.

Side Effect Profiles: Where They Differ

Both drugs share a class-effect adverse event profile: headache, flushing, nasal congestion, and dyspepsia. Rates across large trials are broadly similar, though the specific side effects that predominate differ.

Flushing and Visual Effects

Sildenafil produces flushing in approximately 10% of men and transient visual changes (blue-tinge, blurring) in about 3% 1. Visual effects are dose-dependent and rare at 25 mg but more noticeable at 100 mg. Tadalafil produces flushing in roughly 4% of men and visual symptoms in under 1% of reported cases 2.

Myalgia and Back Pain

Tadalafil produces back pain and myalgia in approximately 5% to 6% of users, a rate higher than sildenafil's 1% to 2% 3. This effect is attributed to PDE11 inhibition in skeletal muscle and typically resolves within 48 hours. Patients should be counseled before starting tadalafil that mild back ache after the first few doses is expected, not alarming.

Cardiovascular Safety

Both drugs are contraindicated with nitrate medications of any form due to additive hypotension. The Princeton Consensus Panel (2012) guidelines classify men with stable cardiovascular disease as low-risk for sexual activity and appropriate for PDE5 inhibitor use after physician review 12. No head-to-head cardiovascular mortality differences between tadalafil and sildenafil have been shown in trial data.

Tadalafil 5 mg daily has shown a modest blood-pressure-lowering effect in men with hypertension (mean SBP reduction 4 to 5 mmHg in some studies), which may be a benefit in certain patients but requires monitoring in others 13.

Drug Interactions and Contraindications

Nitrates

Both tadalafil and sildenafil are absolutely contraindicated with all organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite poppers) due to risk of severe hypotension. This is the most critical drug interaction for both agents 14.

The washout period before nitroglycerin use differs. Because of its longer half-life, tadalafil requires a minimum 48-hour washout before any nitrate can be administered safely. Sildenafil requires 24 hours 15.

CYP3A4 Interactions

Both drugs are metabolized by hepatic CYP3A4. Strong CYP3A4 inhibitors (ritonavir, ketoconazole, itraconazole) substantially raise plasma levels of both drugs. The FDA label for sildenafil recommends a maximum 25 mg dose with ritonavir; the tadalafil label recommends a maximum 10 mg dose no more than once every 72 hours with potent inhibitors 14.

Alpha-blockers (tamsulosin, alfuzosin) combined with either drug can produce symptomatic hypotension. Tadalafil 5 mg daily with tamsulosin 0.4 mg daily has the best-studied safety profile for this combination, supported by data from the MTOPS-related BPH trials 16.

Tadalafil for BPH and LUTS: A Distinct Advantage

Tadalafil 5 mg once daily is the only PDE5 inhibitor with an FDA-approved indication for both erectile dysfunction and benign prostatic hyperplasia / lower urinary tract symptoms (BPH/LUTS). Sildenafil has no approved BPH indication.

The LVHJ trial (N=325) found daily tadalafil 5 mg reduced International Prostate Symptom Score (IPSS) by 4.9 points from baseline versus 2.3 points for placebo (P<0.001) at 12 weeks 17. For men over 50 presenting with both ED and storage/voiding symptoms, tadalafil 5 mg daily addresses both problems with a single daily tablet.

Sildenafil does not produce the same sustained bladder-neck and prostatic smooth muscle relaxation because its short half-life means trough concentrations fall to subtherapeutic levels within 8 to 12 hours.

Dosing Reference

Sildenafil Approved Doses

Sildenafil for ED is approved at 25 mg, 50 mg, and 100 mg taken 30 to 60 minutes before sexual activity, no more than once daily. The standard starting dose is 50 mg. Dose is reduced to 25 mg in men over age 65, men with hepatic impairment, and men on CYP3A4 inhibitors 14.

Tadalafil Approved Doses

Tadalafil for on-demand ED use is approved at 5 mg, 10 mg, and 20 mg taken at least 30 minutes before activity. Daily-dose tadalafil for ED uses 2.5 mg or 5 mg. For BPH/LUTS only, the approved dose is also 5 mg daily. Maximum dose frequency for on-demand use is once every 24 hours 15.

When to Switch from Cialis to Viagra (or Vice Versa)

Switching between PDE5 inhibitors is common and generally safe with appropriate guidance.

Reasons Patients Switch from Tadalafil to Sildenafil

Back pain is the most common clinical reason to switch away from tadalafil. A patient experiencing persistent myalgia after 2 to 3 doses of tadalafil 20 mg may respond better to sildenafil 50 mg. Some men also prefer the shorter, more defined action window, reporting that they feel more "in control" of onset with sildenafil.

Men with hemodynamic sensitivity (borderline hypotension, concurrent alpha-blocker use) may find tadalafil's prolonged effect on blood pressure harder to manage.

Reasons Patients Switch from Sildenafil to Tadalafil

The most common driver is meal timing. Men who frequently eat dinner before intercourse and experience reduced sildenafil efficacy may achieve more consistent results with tadalafil. Men with concurrent BPH and ED gain the dual indication benefit.

A HealthRX clinical review of 430 patients who switched between PDE5 inhibitors over a 24-month period found that 68% who switched from on-demand sildenafil to daily tadalafil 5 mg reported sustained satisfaction at 6-month follow-up, versus 44% who remained on on-demand sildenafil after a dose adjustment. Switching was well-tolerated in all cases when a 24-hour washout separated the last sildenafil dose from the first tadalafil dose.

How to Switch Safely

No pharmacokinetic interaction exists between the two drugs once one is fully cleared. For sildenafil to tadalafil: wait 24 hours after the last sildenafil dose, then begin tadalafil at the starting dose (10 mg on-demand or 5 mg daily). For tadalafil to sildenafil: wait 48 hours after the last tadalafil dose. Start sildenafil at 50 mg unless age or comorbidities indicate 25 mg.

Patients should confirm with their prescriber before switching, particularly if they take alpha-blockers, antifungals, or antiretrovirals.

Cost and Generic Access

Generic sildenafil has been available in the U.S. Since 2017; generic tadalafil launched in 2018. As of 2024, generic sildenafil 100 mg costs approximately $1 to $3 per tablet through major pharmacy chains and telehealth platforms. Generic tadalafil 20 mg runs approximately $2 to $5 per tablet. Daily tadalafil 5 mg (30-count) averages $25 to $50 per month through GoodRx pricing tiers 18.

Cost should not be a barrier to PDE5 inhibitor therapy in 2025. The availability of generics at these price points means most men can access effective ED pharmacotherapy for well under $60 per month without insurance.